Designed to objectively cover the process of bench to bedside development of cardiovascular drug, device and cell therapy, and to bring you the information you need most in a timely and useful format, Cardiovascular Drugs and Therapy takes a fresh and energetic look at advances in this dynamic field.Homing in on the most exciting work being done on new therapeutic agents, Cardiovascular Drugs and Therapy focusses on developments in atherosclerosis, hyperlipidemia, diabetes, ischemic syndromes and arrhythmias. The Journal is an authoritative source of current and relevant information that is indispensable for basic and clinical investigators aiming for novel, breakthrough research as well as for cardiologists seeking to best serve their patients.Providing you with a single, concise reference tool acknowledged to be among the finest in the world, Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. The regular articles and frequent special topical issues equip you with an up-to-date source defined by the need for accurate information on an ever-evolving field. Cardiovascular Drugs and Therapy is a careful and accurate guide through the maze of new products and therapies which furnishes you with the details on cardiovascular pharmacology that you will refer to time and time again.
《心血管药物与治疗》旨在客观地涵盖心血管药物、设备和细胞治疗从实验室到临床的发展过程，并以及时和有用的形式为您提供您最需要的信息，以新鲜和充满活力的眼光看待这一动态领域的进展。高脂血症、糖尿病、局部缺血综合征和心律失常。期刊是当前和相关信息的权威来源，对于致力于创新、突破性研究的基础和临床研究者以及寻求最佳患者服务的心脏病专家来说，是不可或缺的。为您提供公认为世界上最好的单一、简洁的参考工具。心血管药物和治疗在Web of Science和PubMed/Medline以及其他摘要和索引服务中列出。定期的文章和经常性的专题问题为您提供了一个最新的来源，定义为对一个不断发展的领域的准确信息的需要。心血管药物和治疗是一个仔细和准确的指南，通过迷宫的新产品和治疗，为您提供了详细的心血管药理学，您将参考一次又一次。
Dexmedetomidine Preconditioning Protects Cardiomyocytes Against Hypoxia/Reoxygenation-Induced Necroptosis by Inhibiting HMGB1-Mediated Inflammation
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06857-1
“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06873-1
The Role of Thyroid Hormones in Heart Failure
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06870-4
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06892-y
Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06901-0
Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06851-7
Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06907-8
The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06914-9
Activation of T Lymphocytes as a Novel Mechanism in Beta1-Adrenergic Receptor Autoantibody-Induced Cardiac Remodeling
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06856-2
State of the Art Comprehensive Review of Individual Statins, Their Differences, Pharmacology, and Clinical Implications
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06904-x
Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06910-z
Absence of Functional Nav1.8 Channels in Non-diseased Atrial and Ventricular Cardiomyocytes
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06925-6
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06852-6
Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06911-y
Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06864-2
Impact of Ca2+-Sensitive Potassium Channels in Levosimendan-Induced Postconditioning
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06908-7
Cardioprotective Effects of Beta3-Adrenergic Receptor (β3-AR) Pre-, Per-, and Post-treatment in Ischemia–Reperfusion
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06861-5
LncRNA MALAT1 Promotes Oxygen-Glucose Deprivation and Reoxygenation Induced Cardiomyocytes Injury Through Sponging miR-20b to Enhance beclin1-Mediated Autophagy
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06902-z
Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06855-3
The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06917-6
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06906-9
Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06883-z
Resolvin D1 Attenuates Myocardial Infarction in a Rodent Model with the Participation of the HMGB1 Pathway
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06884-y
Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06885-x
Omitting aspirin in PCI patients: Myth or reality?
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06916-7
Activation of T Lymphocytes as a Novel Mechanism in Beta1-Adrenergic Receptor Autoantibody-Induced Cardiac Remodeling—Additional Information About TLR9 Involvement
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06874-0
Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06898-6
HDL-Targeted Therapies During Myocardial Infarction
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06865-1
Effects of PDE-5 Inhibition on the Cardiopulmonary System After 2 or 4 Weeks of Chronic Hypoxia
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06887-9
Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06900-1
Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06890-0
After the AUGUSTUS Trial, Should Apixaban Be the Only Direct Oral Anticoagulant to Be Used in Triple Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention?
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06886-w
Five-Year Outcomes of Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Durable Polymer Drug-Eluting Stents: a Meta-Analysis of Randomized Controlled Trials
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06912-x
Association of Elevated Plasma Homocysteine Level with Restenosis and Clinical Outcomes After Percutaneous Coronary Interventions: a Systemic Review and Meta-analysis
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06866-0
A Novel Epigenetic Drug-Eluting Balloon Angioplasty Device: Evaluation in a Large Animal Model of Neointimal Hyperplasia
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06921-w
Inhibition of Niemann-Pick C1-Like 1 by Ezetimibe Reduces Dietary 5β,6β-Epoxycholesterol Absorption in Rats
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06854-4
My Last Issue—a Farewell to Cardiovascular Drugs and Therapy
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06928-3
Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06882-0
Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06913-w
Plasma from Volunteers Breathing Helium Reduces Hypoxia-Induced Cell Damage in Human Endothelial Cells—Mechanisms of Remote Protection Against Hypoxia by Helium
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06880-2
Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06872-2
HFREF Patients and Atrial Fibrillation: Time to Reconsider the Appropriateness of the Atrial Fibrillation Ablation in This Patient Subset?
来源期刊：Cardiovascular drugs and therapyDOI：10.1007/s10557-019-06881-1
Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06923-8
Medical Misinformation: Vet the Message!
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06859-z
Association of Regulatory Genetic Variants for Protein Kinase Cα with Mortality and Drug Efficacy in Patients with Heart Failure
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06909-6
Chewed or Crushed Administration of Adenosine Diphosphate Receptor Inhibitors in Acute Coronary Syndromes: a Systematic Review and Meta-analysis of Randomized Controlled Trials
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06905-w
Special Issue: British Society for Cardiovascular Research
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06877-x
Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06920-x
From the Choice of a Regimen to the Choice of an Intensity: Changing Perspective in the Antithrombotic Therapy of Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
来源期刊：Cardiovascular Drugs and TherapyDOI：10.1007/s10557-019-06903-y
